MediciNova, Inc. (NASDAQ: MNOV), a biopharmaceutical company, is dedicated to acquiring and developing innovative, small-molecule therapeutics designed to treat diseases with medical needs that are currently unmet. By strategically forming alliances with other pharmaceutical companies, the company holds rights to a diversified portfolio of clinical and preclinical product candidates. MediciNova believes each of these candidates has a well-characterized and unique therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. For further information, visit the Company’s web site at www.medicinova.com.
- 18 years ago
QualityStocks
MediciNova, Inc. (NASDAQ: MNOV)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Closer to Regulatory and Commercial Milestones
Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC hydrogel-based cartilage regeneration technology toward key clinical, regulatory…
-
Wrap Technologies Inc. (NASDAQ: WRAP) Positions Non-Lethal Innovation at the Center of Public Safety Reform
WRAP offerings illustrate a broader industry trend toward building connected ecosystems rather than standalone products.…
-
Brownfield Gold Projects Could Hold an Edge in Today’s Permitting Environment
Disseminated on behalf of Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising.…